Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251810211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sarfaraz K Niazi. Beteiligte Einrichtung: College of Pharmacy, University of Illinois, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Biological Availability, Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Although decades of intensive drug discovery efforts to treat neurodegenerative disorders (NDs) have failed, around half a million patients in more than 2000 studies continue being tested, costing over USD 100 billion, despite the conclusion that even those drugs which have been approved have no better effect than a placebo. The US Food and Drug Administration (FDA) has established multiple programs to innovate the treatment of rare diseases, particularly NDs, providing millions of USD in funding primarily by encouraging novel clinical trials to account for issues related to study sizes and adopting multi-arm studies to account for patient dropouts. Instead, the FDA should focus on the primary reason for failure: the poor bioavailability of drugs reaching the brain (generally 0.1% at most) due to the blood–brain barrier (BBB). There are several solutions to enhance entry into the brain, and the FDA must require proof of significant entry into the brain as the prerequisite to approving Investigational New Drug (IND) applications. The FDA should also rely on factors other than biomarkers to confirm efficacy, as these are rarely relevant to clinical use. This study summarizes how the drugs used to treat NDs can be made effective and how the FDA should change its guidelines for IND approval of these drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, University of Illinois, Chicago, IL 60612, USA.
ORCID-Profile: Sarfaraz K Niazi
Zitieren
APA
Niazi, S. K. (2024). Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251810211
Vancouver
Niazi SK. Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251810211
BibTeX
@article{Niazi2024,
author = {Niazi, Sarfaraz K},
title = {Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251810211}
}
EUVIMED